Trials / Unknown
UnknownNCT04144855
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection
A Phase I, Open-label, Multicenter, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in patients with advanced malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3474 injection | This is a kind of heat shock protein (HSP90) inhibitor. |
Timeline
- Start date
- 2018-11-27
- Primary completion
- 2020-11-27
- Completion
- 2021-05-30
- First posted
- 2019-10-30
- Last updated
- 2019-10-30
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04144855. Inclusion in this directory is not an endorsement.